InSite Vision to Hold 2003 Third Quarter Financial Results Conference Call on
November 13
ALAMEDA, Calif., Nov. 10 /PRNewswire-FirstCall/ -- InSite Vision Incorporated
-- an ophthalmic therapeutics, diagnostics and drug-delivery company -- today
announced that the Company will release 2003 third quarter financial results
after market close Thursday, November 13, 2003. S. Kumar Chandrasekaran, Ph.D.,
chief executive officer, president and chief financial officer, and Sandra
Heine, senior director of finance, will host an investment-community conference
call beginning at 5:00 p.m. Eastern Time on Thursday, November 13, 2003 to
discuss these results and to answer questions.
Individuals interested in listening to the conference call may do so by dialing
(888) 803-7364 for domestic callers or (706) 634-1033 for international callers. A telephone replay will be available for 48 hours following the conclusion of
the call by dialing (800) 642-1687 (domestic) or (706) 645-9291 (international),
and entering reservation code 3970238.
The live conference call will also be available via the Internet on the investor
relations section of the Company's Web site at http://www.insitevision.com/, and
a recording of the call will be available for 90 days following the completion
of the call.
InSite Vision is an ophthalmic products company focused on glaucoma, ocular
infections and retinal diseases. In the area of glaucoma, the Company conducts
genomic research using TIGR and other genes. A portion of this research has
been incorporated into the Company's OcuGene glaucoma genetic test for disease
management, as well as ISV-205, its novel glaucoma therapeutic. ISV-205 uses
InSite Vision's proprietary DuraSite(R) drug-delivery technology, which also is
incorporated into the ocular infection products ISV-401 and ISV-403, and InSite
Vision's retinal disease program. Additional information can be found at
http://www.insitevision.com/.
This press release and the telephone conference referenced herein may contain,
among other things, certain statements of a forward-looking nature relating to
future events or the future business performance of InSite Vision. Such
statements entail a number of risks and uncertainties, including but not limited
to: InSite Vision's immediate need for significant additional funding to
continue its operations; the effects of its expense control activities on its
operations and product development, its ability to obtain regulatory approval
and market acceptance of its products, including ISV-403, OcuGene, ISV-401 and
ISV-205; its ability to maintain and develop additional collaborations and
commercial agreements with corporate partners, including those with respect to
ISV-403, ISV-401 and ISV-205; its reliance on third parties for the development,
marketing and sale of its products; and the initiation and results of
preclinical and clinical studies, its ability to adequately protect its
intellectual property and; determinations by the U.S. Food and Drug
Administration, including those with respect to ISV-403, OcuGene, ISV-401 and
ISV-205. Reference is made to the discussion of risk factors detailed in InSite
Vision's filings with the Securities and Exchange Commission, including its
annual report on Form 10-K for the 2002 fiscal year and Quarterly Report on Form
10-Q for the fiscal quarter ended June 30, 2003. Any projections in this release
are based on limited information currently available to InSite Vision, which is
subject to change. Although any such projections and the factors influencing
them will likely change, InSite Vision undertakes no obligation to update the
information, since InSite Vision may only provide guidance at certain points
during the year. Such information speaks only as of the date of this release or
the date of the telephone conference. Actual events or results could differ
materially and no reader of this release should assume later that the
information provided today or in the live telephone conference is still valid.
Note to Editors: OcuGene is written with a "small cap" G; if doing so is not
possible, please use an upper case G. InSite Vision Incorporated, InSite
Vision, DuraSite and OcuGene are trademarks of InSite Vision Incorporated. Other
trademarks that may be mentioned in this release are the intellectual property
of their respective owners.
For further information, please contact S. Kumar Chandrasekaran, CEO, or Sandra
Heine, Director of Finance, +1-510-865-8800, both of InSite Vision Incorporated;
or Investors, Bruce Voss, , or Jody Cain, , both of Lippert/Heilshorn &
Associates, Inc., +1-310-691-7100, or Media, Chenoa Taitt, , or Michael Hopkins,
, both of Lippert/Heilshorn & Associates, Inc., +1-212-838-3777, all for InSite
Vision Incorporated. DATASOURCE: InSite Vision Incorporated CONTACT: S. Kumar Chandrasekaran, CEO, or Sandra Heine, Director of Finance, +1-510-865-8800, both of InSite Vision Incorporated; or Investors, Bruce Voss, , or Jody Cain, , both of Lippert/Heilshorn & Associates, Inc., +1-310-691-7100, or Media, Chenoa Taitt, , or Michael Hopkins, , both of Lippert/Heilshorn & Associates, Inc., +1-212-838-3777, all for InSite Vision Incorporated Web site: http://www.insitevision.com/
|